Stop bladder cancer coming back with medicine after bladder surgery
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether putting chemotherapy medicine directly into the bladder right after surgery helps prevent bladder cancer from coming back. It compares gemcitabine versus epirubicin given as an immediate bladder “wash-in.”
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a bladder cancer tumor that’s being removed by transurethral surgery (resection), either a new primary tumor or a recurrence
- Your surgery removed the tumor completely enough, and your pathology fits non–muscle-invasive bladder cancer patterns the study allows
- You have blood counts in safe ranges: kidney function (creatinine) under 2.2 mg/dL, white blood cells at least 3,000, and platelets between 75,000 and 500,000
- Your urine test before surgery shows no infection (sterile/negative urine culture)
- Imaging (CT urography) within the last 3 months shows no signs of cancer in the upper urinary tract (kidneys/ureters)
- You can be considered well enough for treatment (performance status 0 to 1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether putting two chemotherapy drugs (gemcitabine and docetaxel) directly into the bladder can treat low-grade bladder cancer that is at intermediate risk. The goal is to see if this approach can help people avoid more invasive treatments.
This study tests a more targeted way to treat low-grade bladder cancer using chemotherapy placed directly into the bladder. Before treatment, your cancer cells are grown in the lab to see which drug works best for you.
This trial tests a combination of two chemotherapy drugs (gemcitabine and docetaxel) given directly into the bladder to treat high-risk non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. It's for people who cannot or choose not to have their bladder removed.
This study tests a combination of two chemotherapy drugs, mitomycin-C and gemcitabine, given directly into the bladder for people with high-risk bladder cancer that hasn't been controlled with BCG therapy. It's an option for those who can't or don't want to have their bladder removed.
This study compares two standard treatments for high-grade non-muscle-invasive bladder cancer that has come back after initial treatment: medication placed directly into the bladder (intravesical therapy) or bladder removal surgery (cystectomy). The goal is to see which option works better for patients like you.
This study tests a new way to give a chemotherapy drug during bladder surgery to help stop the cancer from returning. It is for people with a type of bladder cancer that has not spread into the muscle.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.